Stuart A. Arbuckle - Feb 24, 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, COO
Signature
/s/ Joy Liu, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Feb 24, 2023
Transactions value $
-$2,810,055
Form type
4
Date filed
2/28/2023, 03:47 PM
Previous filing
Feb 24, 2023
Next filing
Apr 4, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Tax liability -$1.36M -4.71K -7.11% $289.12 61.6K Feb 24, 2023 Direct
transaction VRTX Common Stock Sale -$1.1M -3.83K -6.23% $287.16 57.8K Feb 27, 2023 Direct F1, F2, F3
transaction VRTX Common Stock Sale -$115K -400 -0.69% $287.59 57.4K Feb 27, 2023 Direct F1, F2, F4
transaction VRTX Common Stock Sale -$231K -800 -1.39% $288.92 56.6K Feb 27, 2023 Direct F1, F2, F5
holding VRTX Common Stock 140 Feb 24, 2023 401(k)
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
F2 Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $287.16 (range $286.57 to $287.51).
F4 Open market sales reported on this line occurred at a weighted average price of $287.59 (range $287.57 to $287.60).
F5 Open market sales reported on this line occurred at a weighted average price of $288.92 (range $288.57 to $289.38).